Squarepoint
ETTX

Squarepoint’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Squarepoint’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-91,725
Closed -$196K – 3937
2021
Q1 		$196K Buy
91,725
+32,081
+54% +$91.2K ﹤0.01% 2706
2020
Q4 		$147K Buy
+59,644
New +$117K ﹤0.01% 2622

Other funds holding ETTX

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Squarepoint's ETTX Position: Q2 2021 in Review

Squarepoint sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q2 2021, closing a stake of 91,725 shares — an estimated $196K sold.

Squarepoint first reported a position in ETTX in Q4 2020 and held it in 2 quarters. The position peaked at $196K in Q1 2021. 24 funds tracked by Wall St. Rank hold ETTX as of Q2 2021.

  • Squarepoint reported no remaining Entasis Therapeutics Holdings Inc. position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 91,725 Entasis Therapeutics Holdings Inc. shares in Q2 2021, an estimated $196K.
  • Squarepoint first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2020 and held it in 2 quarters.
  • Squarepoint's Entasis Therapeutics Holdings Inc. position peaked at $196K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.